+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H2 2018

  • PDF Icon

    Drug Pipelines

  • 67 Pages
  • September 2018
  • Region: Global
  • Global Markets Direct
  • ID: 4621796
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H2 2018

Summary

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) pipeline Target constitutes close to 14 molecules. The latest report Orexin Receptor Type 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Orexin receptor type 1 (Ox1R or OX1) is a protein that is encoded by the HCRTR1 gene. The orexin 1 receptor (OX1) is a G-protein coupled receptor that is highly expressed in projections from the lateral hypothalamus and is involved in the regulation of feeding behavior. OX1 selectively binds the orexin-A neuropeptide.

The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 2, 8 and 2 respectively. Report covers products from therapy areas Central Nervous System and Respiratory which include indications Nicotine Addiction, Insomnia, Binge Eating Disorder, Addiction, Alcohol Addiction, Drug Addiction, Anxiety Disorders, Dementia Associated With Alzheimer's Disease, Major Depressive Disorder, Narcolepsy, Obstructive Sleep Apnea, Opium (Opioid) Addiction, Panic Disorders, Parkinson's Disease, Pathological Gambling and Sleep Disorders.

Furthermore, this report also reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)

  • The report reviews Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics


Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Introduction
Report Coverage
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Overview
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Companies Involved in Therapeutics Development
Chronos Therapeutics Ltd
Eisai Co Ltd
Heptares Therapeutics Ltd
Idorsia Pharmaceutical Ltd
Indivior Plc
Johnson & Johnson
OptiNose US Inc
Yangtze River Pharmaceutical Group
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles
ACT-539313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-4X3256 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-010018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EORA-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-6641 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-3215 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lemborexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nemorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Orexin 1 and 2 Receptors for Insomnia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Mollecules to Antagonize HCRTR1 for Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suvorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Dormant Products
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Product Development Milestones
Featured News & Press Releases
Jul 24, 2018: C4X Discoverys C4X3256 programme awarded $480k grant from the US National Institute on Drug Abuse
Jul 19, 2018: Eisai announce presentation on lemborexant at (AAIC) 2018
Jul 02, 2018: Eisai to Give Oral Presentation on Results of Phase III Head-to-head Clinical Study of Lemborexant in Insomnia Disorder at 43rd Annual Meeting of the Japan Society of Sleep Research
Jun 11, 2018: Idorsia initiates a Phase 3 registration program with nemorexant (ACT-541468) for the treatment of insomnia
Jun 05, 2018: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting
May 22, 2018: Eisai and Purdue Pharma Announce Key Phase 1 Clinical Studies of Lemborexant to be Presented at the 32nd Annual SLEEP Meeting
Mar 07, 2018: Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
Dec 07, 2017: Eisai and Purdue Pharma L.P. Presented Lemborexant Data from Research Studies at ACNP Annual Meeting
Nov 13, 2017: C4XD presents data on its lead addiction programme: Orexin-1 antagonist
Oct 31, 2017: Eisai to Present Latest Data on lemborexant at 10th Clinical Trials on Alzheimer's Disease
Jul 28, 2017: ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia
Oct 28, 2016: Eisai To Initiate Phase II Clinical Study Of Dual Orexin Receptor Antagonist Lemborexant In Patients With Irregular Sleep-Wake Rhythm Disorder And Dementia
Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia
Feb 01, 2016: OptiNose Announces Pipeline Project to Evaluate Nose-to-Brain Application of Bi-Directional Breath Powered Technology Selected for Norwegian Government Funding
May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Chronos Therapeutics Ltd, H2 2018
Pipeline by Eisai Co Ltd, H2 2018
Pipeline by Heptares Therapeutics Ltd, H2 2018
Pipeline by Idorsia Pharmaceutical Ltd, H2 2018
Pipeline by Indivior Plc, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by OptiNose US Inc, H2 2018
Pipeline by Yangtze River Pharmaceutical Group, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Chronos Therapeutics Ltd

  • Eisai Co Ltd

  • Heptares Therapeutics Ltd

  • Idorsia Pharmaceutical Ltd

  • Indivior Plc

  • Johnson & Johnson

  • OptiNose US Inc

  • Yangtze River Pharmaceutical Group